Anti Inflammatory News and Research

RSS

Study highlights increased consumption of opioids in patients with osteoarthritis

Fentanyl, tramadol or tilidine: New European figures show that even in Europe increasingly more people are taking opioids for pain connected with rheumatic and musculoskeletal diseases.

5 Jun 2020

U.K. doctors test lipid ibuprofen as COVID-19 treatment

The non-steroidal anti-inflammatory drug (NSAID) Ibuprofen is being tested as a potential treatment for the coronavirus disease (COVID-19). Doctors in the United Kingdom rolled out a clinical trial of the everyday painkiller to see if it reduces respiratory failure in patients experiencing severe COVID-19 disease.

4 Jun 2020

Potential new immunotherapy for critical COVID-19

Researchers at the Chongqing Medical University in China have identified a cytokine that could serve as a potential candidate for treating patients with severe coronavirus disease 2019 (COVID-19).

4 Jun 2020

Intranasal delivery of MSC-EVs shows promise for treating Alzheimer's disease

In the search for a cure for Alzheimer's disease, mesenchymal stem cells and their derived extracellular vesicles (MSC-EVs) offer much promise, thanks to their protective and anti-inflammatory properties.

4 Jun 2020

New project investigating role of B cells in cardiovascular disease receives $6.5 million grant

Christoph Binder, Professor of Atherosclerosis Research at MedUni Vienna, is to coordinate an international research network investigating the role of B cells in cardiovascular disease.

2 Jun 2020

Study highlights potential benefits of new drug for inflammatory diseases

New research conducted by the University of Liverpool and AKL Research and Development Ltd, published in Inflammopharmacology, highlights the potential benefits of a new drug treatment on the human body's immune response in inflammation.

1 Jun 2020

Ruxolitinib shows promise in severe COVID-19

An anti-inflammatory drug Ruxolitinib has shown promising results in the treatment of severe coronavirus disease COVID-19. The study titled, “Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial,” was published as a pre-proof for the Journal of Allergy and Clinical Immunology.

31 May 2020

Transgenic mouse model of HLH may play key role in saving lives during COVID-19

A transgenic mouse developed at Cincinnati Children's to model the deadly childhood immune disease HLH (hemophagocytic lymphohistiocytosis) may play a key role in saving lives during the COVID-19 virus pandemic.

28 May 2020

ACE2 receptors in the kidney not linked to high BP or RAS blockers

Even as the COVID-19 pandemic continues to smolder and flare up in various parts of the world, researchers are still trying to make sense of the virus, its routes of spread, its target tissues, and the immune responses it induces. One crucial piece of knowledge is that the primary viral receptor is a human enzyme called angiotensin-converting enzyme 2 (ACE2).

27 May 2020

Scientists discover two anti-inflammatory drugs that inhibit COVID-19 infection

Since the outbreak of the COVID-19 pandemic and its rapid spread, the scientific community has been working on developing an effective treatment for the virus responsible for the disease.

27 May 2020

COVID-19 Rapid Research Fund allows coronavirus research in Ontario and London

Sepsis is a life-threatening condition. It occurs when the body's response to an infection is out of balance, triggering hyperinflammation that can damage multiple organs.

27 May 2020

Scientists are collecting big data to expedite the fight against COVID-19

A nationwide collaboration of clinicians, informaticians and other biomedical researchers aims to turn data from hundreds of thousands of medical records from coronavirus patients into effective treatments and predictive analytical tools that could help lessen or end the global pandemic.

27 May 2020

Investigational antiviral superior to standard of care for treating COVID-19 patients

The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in The New England Journal of Medicine.

27 May 2020

Giving good bacteria to stressed mothers prevents autism-like disorder in offspring

Giving beneficial bacteria to stressed mothers during the equivalent of the third trimester of pregnancy prevents an autism-like disorder in their offspring, according to a new animal study by University of Colorado Boulder researchers.

26 May 2020

Novel testing system predicts outcomes in patients with sepsis

More than 1.7 million Americans develop sepsis each year, and more than 270,000 die from it. The condition--which happens when the body has an extreme response to a bacterial or viral infection, causing a chain reaction that can lead to organ failure and death--has few strategies for treatment.

26 May 2020

'Good' bacteria have a niche in our noses, study suggests

Beneficial strains of bacteria residing in our guts, genital tracts, and skin have been shown to play a role in human health, and now, researchers publishing May 26 in the journal Cell Reports suggest that some of these "good" bacteria also have a niche in our noses.

26 May 2020

Can Chlorpromazine help treat COVID-19?

A new research paper published in the journal L'Encéphale in May 2020 reports on the planned ReCoVery Study, which will examine the possibility of repurposing the antipsychotic drug chlorpromazine for the treatment of COVID-19.

25 May 2020

Using Qigong to manage COVID-19 in older adults

A recent study published in The American Journal of Geriatric Psychiatry in May 2020 reports on the possible usefulness of the integrative practice called Qigong to prevent and manage COVID-19 in older adults.

25 May 2020

Capillary leakage important in COVID-19 respiratory distress

Now, a new study published on the preprint server medRxiv reports the pivotal role played by protein leakage through lung capillaries and promotes the use of serum albumin as a biomarker of disease progression and severity.

24 May 2020

Study evaluates the effectiveness of interferon beta 1b in COVID-19 pneumonia

As the world struggles to overcome the current COVID-19 pandemic with non-pharmacological interventions, in the absence of an effective drug or vaccine, existing immunomodulators are being repurposed. A new study published on the preprint server medRxiv* in May 2020 shows no clinical benefit to the use of one such drug, called interferon beta 1b (IFN beta1b).

22 May 2020